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The clinical aspects and anatomopathological patterns of 150 postmenopausal women were studied using the progestogen challenge
test. An endometrial biopsy was obtained and submitted to the progestogen test. A histopathological analysis of the uterine mucosa
from women with a positive progestogen test revealed that the endometrium was active in 44 percent of cases and atrophic or inactive
in 56 percent. In contrast, among women with a negative response, the endometrium was atrophic in 94 percent of cases and active
in 6 percent. Analysis of clinical aspects did not show significant differences between groups in terms of age; age at menarche and at
menopause; fasting blood glucose levels; or body mass. However, postmenopausal time was significantly shorter for women with a
positive test, with a correlation between postmenopausal time of one to two years and test positivity. The progestogen challenge test
for the detection of atrophic endometrium presented 78.57 percent sensitivity, 77.05 percent specificity, 44 percent positive predictive
value, and 94 percent negative predictive value. Thus, when negative, the test is highly valuable, indicating the presence of atrophic
endometrium in 94 percent of cases. False-negative results occurred in only 6 percent of the subjects, with no case of hyperplasia
detected. However, when the response to the test was positive, the endometrium was atrophic in 56 percent of the cases. We suggest
that, in order to avoid invasive procedures, the progestogen challenge test be combined with other methods such as transvaginal
ultrasonography.
UNITERMS: Endometrium. Progesterone. Menopause.
INTRODUCTION
According to the International Menopause Society,the climacteric is defined as the transition betweenthe period of greatest reproductive capacity
(menacme) and old age. 1.2 With improved socio-economic
conditions worldwide, a related increase in population
longevity has occurred. Consequently a greater number of
women have reached climacteric. Thus, 90 percent of the
North American female population now reaches menopause,
with a mean life expectancy of 80 years. The mean age at
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onset of menopause is 51.4 years, indicating that women
will have approximately 30 years of life after menopause.3
If the trend is that women will spend approximately
30 percent of their life in a postmenopausal condition,
occurrences during this period will directly affect their
quality of life. With further developments in the field of
medicine, there is the possibility of ensuring a better quality
of life for postmenopausal women.
Many studies have been conducted on the auxiliary
methods of treatment during menopause, especially in
terms of the investigation of the uterine mucosa, an
important site of precancerous and carcinomatous lesions.
Regressive histological patterns are preponderant during
the postmenopausal period as a direct result of the fall in
estrogen levels;1.4 cancer of the endometrium is considered
to be a disease predominent among postmenopausal
women, with a frequency of 80 percent during this period.s
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Many procedures have been used to determine the
real status of the uterine mucosa in menopausal women.
During the last decade, the endometrial biopsy has been
recognized as a useful and effective technique. As it is
carried out in the laboratory, causing little patient
discomfort and offering high diagnostic accuracy, the
procedure has permitted a drastic reduction in the number
of curettages and has optimized gynecological
approaches. 6.7
The cost of an endometrial biopsy is approximately
10 times less than that of uterine curettage, and the
procedure involves a lower surgical risk and provides
accuracy ranging from 95 to 98 percent when compared
to curettage or other surgical procedures. III A biopsy,
however, is still an invasive technique.
There are still other non-invasive methods that have
been used to study the uterine mucosa. Among them is
the progesterone challenge test or the test using synthetic
progestogens. In 1980, GAMBRELL et al. utilized and
definitely sanctioned the use of the test for menopausal
women. They applied the test to 5263 postmenopausal
women in order to identify patients at risk for developing
hyperplasia and carcinoma of the endometrium. When
genital bleeding occurred, they repeated the progestogen
test monthly for a varying period of time until the test
became negative. Among women not submitted to
hormonal treatment, approximately 35 percent experienced
bleeding in response to the testy.lo
Later, HANNA et al. (1983) administered oily
progesterone intramuscularly in 100 mg doses to 30
postmenopausal and asymptomatic women, 10 of whom
were using equine-conjugated estrogens. They had
previously obtained an endometrial biopsy from each
woman from the four quadrants using a Novak curette.
Five responded to the test with bleeding; of these patients,
three presented endometrial hyperplasia (60 percent) and
two atrophic endometrium (40 percent). In the second
group of 10 women, known to have a hyperplastic uterine
mucosa, they obtained one false-negative result (10
percent). The authors therefore suggested that the
progestogen challenge test be added to the medical arsenal
for the evaluation of climacteric women. I I
ERNY et al. (1986) later performed the progesterone
test 1,633 times, with a 12.8 percent rate of positive tests.
Among 156 women with a positive test submitted to
curettage, the anatomopathological findings revealed an
atrophic endometrium in 79 (50.6 percent). In the group
with negative tests, one woman had adenocarcinoma of
the endometriumY Other researchers have obtained 71.4
percent test accuracy and recommended the use of the test
for all postmenopausal women, and the investigation of
endometrial histology for those with a positive response.13
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In a pioneering study in Brazil, WEHBA (1988)
compared the histopathological analysis of the
endometrium obtained by curettage from 50
postmenopausal women with a positive or negative result
on the progestogen challenge test, in order to study the
value of the test in the detection of hyperplastic lesions of
the endometrium. The author obtained 12 positive results
(24 percent) and 38 negative results (76 percent). In the
positive tests, the endometrium showed proliferative
activity in all cases, and was hyperplastic in 50 percent.
When the test was negative, the endometrium presented
early proliferative activity in only 13.2 percent. In the
remaining patients, atrophy was detected in 73.7 percent,
or the material was considered inadequate in 13.2 percent.
This study made a decisive contribution to the introduction
of the progestogen challenge test in Brazil as a routine
approach to the monitoring of postmenopausal women.14
MACIA et al. (1993) later studied asymptomatic
postmenopausal women not submitted to hormonal
replacement. According to these researchers, the
progestogen challenge test presented 100 percent
specificity, as it was negative in all patients with an atrophic
endometrium. In addition, sensitivity was 76 percent as
among the 89 women with a negative test, and the
endometrium was proliferative or hyperplastic in three. IS
Others authors observed that 26 of 187 asymptomatic
postmenopausal women not submitted to hormone therapy
did not present atrophy of the uterine mucosa. The test
was positive in 16 of these patients (61.5 percent), but
negative in 10 (38.4 percent). These findings show that
false-positive results may be obtained with the progestogen
challenge test. 16
However, few studies are available that compare a
posi ti ve or negati ve response to the progestogen
challenge test with the respective histopathological
findings. Thus, the objectives of the present study were
to evaluate women with positive and negative
progestogen challenge tests in terms of age; age at
menarche and menopause; duration of menopause; body
mass index; fasting blood glucose levels and endometrial
histopathology; and to calculate the sensitivity and
specificity, as well as the positive and negative predictive
values of the progestogen challenge test, with respect to
the histological type of endometrium.
PATIENTS AND METHOD
The study was conducted on 150 postmenopausal
women seen at the Sector of Endocrine Gynecology and
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Climacteric of the Discipline of Gynecology, Escola
Paulista de Medicina, from September 1992 to November
1993. A woman was considered postmenopausal when she
was more than 40 years old, with at least one year of
amenorrhea and high levels of follicle stimulating hormone
(FSH) and luteinizing hormone (LH).1.14
The exclusion criteria were as follows:
non-spontaneous menopause; postmenopausal genital
bleeding; hormonal replacement treatment during the
climacteric; liver, heart, kidney and thyroid disease;
cancer of the endometrium or of the breast; and
conditions that would prevent transvaginal ultrasound
examination or anatomopathological study of the
endometrium. Each patient was submitted to clinical and
hormonal evaluation and to an anatomopathological
examination of the endometrium, and the following
clinical data was recorded: age, race, marital status, age
at menarche and at menopause, duration of menopause,
weight, height, and body mass index. Body mass index
was calculated by the weight/height2 ratio.'7
Endometrial fragments were obtained with a
modified Novak curette. The biopsy always included the
anterior, posterior and lateral walls of the uterine cavity.
The material destined for histological study by light
microscopy was immediately placed in 10 percent formalin
and then embedded in paraffin. Blocks were cut with a
microtome adjusted to 5 /lm thickness, and slides were
stained with hematoxylin-eosin. The endometrium was
then studied morphologically by a single examiner.
The morphologic study was carried out on the entire
extension of the histological section using a common
binocular Zeiss microscope with a 10x eyepiece and
objectives with 4 to 100x magnification.
The endometrium was classified histologically as:
1. inactive: atrophic endometrium.
2. active: any endometrial pattern other than atrophy,
i.e., proliferative, mixed, secretory, with polyps,
and typical or atypical hyperplasia.
The progestogen challenge test was performed after
the endometrial biopsy. Medroxyprogesterone was
administered by the oral route at the dose of 10 mg/day
for 10 consecutive daysy.15.IRThe test was performed only
seven to 10 days after the uterine mucosal biopsy in order
to prevent a possible confusion between bleeding occurring
naturally after the procedure, and a positive response to
the test. The test was considered positive when bleeding
occurred, and negative when no bleeding occurred.
On the basis of the progestogen challenge test, we
obtained a group of 50 women with a positive result (Group
I), and a control group of 100 women with a negative result
(Group II). The women were also classified into four
groups according to how long they had been menopausal:
• Group 1, women with a menopause duration of one
to two years;
• Group 2, women with a duration of three to five years;
• Group 3, women with a duration of six to 10 years;
• Group 4, women who had been menopausal for 11
or more years.
Data were analyzed statistically by the following
nonparametric tests, taking into consideration the nature
of the values of the variables studied: Mann-Whitney test,
chi-square testl9 (p<0.05), test of specificity and sensitivity,
and positive and negative predictive value.20 The level of
significance was set at 5 percent, and significant values
are indicated by an asterisk.
RESULTS
Table 1 lists the data pertaining to the histological
pattern of the endometrium of women with a positive and
negative test. Among women with a positive progestogen
challenge test (Group I), a histopathological analysis of
the uterine mucosa revealed an active endometrium in 44
percent of cases, and atrophic or inactive endometrium in
56 percent. In the group with an active endometrium, the
endometrium was proliferative in 16 percent of cases,
secretory in 10 percent, with typical hyperplasia in 8
Table 1
The histopathological pattern of the endometrium
of women with a positive (Group I) and negative
(Group II) progestogen challenge test.
Histopathology Group I Group II
N % N 0/0
Atrophic (inactive) 28 56.0 94 94.0
Active
Proliferative 8 16.0 2 2.0
Secretory 5 10.0 2 2.0
Typical hyperplasia 4 8.0
Mixed 2 4.0 1.0
Poplyp 2 4.0 1.0
Atypical hyperplasia 2.0
Total 50 100.0 100 100.0
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Table 2
The means values of age, age at menarche and at menopause,
postmenopausal time, body mass index (8MI) and glucose levels
(mg/dl) in women with positive (Group I) and negative (Group II)
progestogen challenge test.
Group
II
Age
54
55.1
Age at
Menarche
13.1
13.3
Age at
Menopause
48.1
47.8
Postmenopausal
Time (Yr)
5.8*
7.2*
BMI
27.4
26.5
Glucose
Levels
107.3
102.1
of individuals with an active
endometrium when the test is positive,
was 44 percent. The negative
predictive value was 94 percent, i.e.,
when the test was negati ve, the
endometrium was inactive in 94
percent of the cases.
DISCUSSION
Mann-Whitney test (Group I x Group II)
zcritical = 1.96
Age Age at Menarche Age at Menopause
zcal = 0.85 zcalc = 0.67 zcalc = 0.61
percent, with a polyp in 4 percent, mixed in 4 percent, and
with atypical hyperplasia in 2 percent.
Among women with a negative response, the
endometrium was atrophic in 94 percent of cases and
active in 6 percent. Among the latter cases, the
endometrium was secretory in 2 percent, proliferative
in 2 percent, mixed in 1 percent, and with an
endometrial polyp in 1 percent.
Table 2 lists data about women with a positive (Group
I) and negative (Group II) test in terms of age, age at
menarche and at menopause, postmenopausal time period,
body mass index, and fasting blood glucose levels. After
analysis by the Mann-Whitney test, only postmenopausal
time was significantly shorter in women with a positive test,
while the remaining parameters did not differ significantly
between groups. Thus, it was demonstrated that menopausal
time was significantly shorter in the group of women with a
positive progestogen challenge test (a mean of 5.8 years for
Group I and of 7.2 years for Group II).
Table 3 shows the relationship between
postmenopausal time and response to the test. It was
concluded that there was a significant association between
a menopausal time of 1 to 2 years and a positive test.
The sensitivity, specificity, and positive and negative
predictive values of the test are listed in Table 4. Sensitivity,
defined as the ability of the test to detect individuals with
a non-atrophic endometrium, was 78.57 percent.
Specificity, i.e., the ability of the test to select normal
women with an atrophic endometrium, was 77.05 percent.
The positive predictive value, defined as the percentage
Glucose Levels
zcalc = 0.98
PostmenopausalTime
zcalc = 2.33*
Group I < Group II
8MI
zcalc = 1.11
The endometrium differs from
other human tissues mainly by being
the target of female sex steroids. Its
development and regression cycles are
tied to the cyclic estroprogestative
oscillations. Thus, it represents a
hormone-dependent mucosa that
reflects the endocrine activity of
human gonads.
Our histopathological findings, listed in Tables 1
and 2, demonstrate that an inactive endometrium was
detected in 94 percent of the women with a negative
progestogen challenge test, and in 56 percent of women
with a positive test. To determine the value of the test
by discriminating between populations, especially with
respect to eventual risk factors for neoplasias of the
endometrium, we compared some variables between
Groups I (negative test) and II (positive test), listed in
Table 2. We deduced that there were no significant
differences between women with a positive or negative
test in terms of age, age at menarche, age at menopause,
body mass index, or fasting blood glucose levels.
In our study, the mean age of women with a positive
progestogen challenge test was 54 years, and the mean
age of women with a negative test was 55.1 years. Analysis
of the literature did not reveal significant differences
between the two groups in terms of age.13.14.21We also
Table 3
Postmenopausal time in .Group I and II.
Postmenopausal Group I Group II Total
time (years) N 0/0 N %
1-2 25 50.0 24 24.0 49
3-5 8 16.0 31 31.0 39
6 -10 8 16.0 23 23.0 31
11+ 9 18.0 22 22.0 31
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found no differences in terms of age at menarche or age at
menopause. WEHBA (1988) detected a significantly lower
age at menarche among patients with a positive test, but
did not observe the same phenomenon with respect to age
at menopause.14
Another risk factor for carcinoma of the endometrium
considered in the present study was diabetes mellitus. A
quite controversial factor, diabetes mellitus has been
considered to result from other variables, especially
obesity.22.23 Indeed, obesity leads to increased estrogen
levels in postmenopausal women and consequently
represents an important risk factor for endometrial
carcinoma.24
HEMPEL et al. (1988) also applied the progestogen
challenge test to groups of diabetic and non-diabetic
menopausal women. Despite mentioning diabetes mellitus
as a risk factor for cancer of the endometrium, the authors
did not report a significantly higher number of positive
tests in the diabetic group.24 Similarly, WEHBA (1988)
did not detect an association of positivity with fasting blood
glucose levels.'4
The literature has not observed differences in body
mass index between women with positive and negative
tests.14.21 Our study also showed no significant
differences in fasting blood glu~ose levels and body
mass index between the groups with positive and
negative tests (Table 2).
On the other hand, postmenopausal time was
significantly longer in women with a negative test (mean,
7.2 years) compared to women with a positive test (mean,
5.8 years). ,We further divided the women according to
menopausal time and submitted their data to statistical
analysis (Table 3). The group of women with menopausal
time of one to two years presented a significant association
with a positive progestogen challenge test. These findings
can be explained by remembering that circulating estrogen
levels are increased during peri menopause, with a slow
decline occurring over subsequent years.25 Furthermore,
metabolic clearance and production of estrone and
estradiol decrease with passing time.
Thus, the proliferative and hyperplastic histological
patterns occurring during the postmenopausal period are
usually observed during the first years after the onset of
menopause, with the incidence of uterine mucosal atrophy
increasing with postmenopausal time.16 Thus, a greater
positivity of the test is to be expected during the first years
after menopause. VALENZUELA et al. (1993) concluded
that women with a postmenopausal time of five years or
more present a lower risk of positivity to the test.21
Few authors have related the progestogen challenge
test to the histological investigation of the endometrium,
Table 4
The sensitivity, specificity, positive and negative
predictive value ot'progestogen challenge
test in postmenopause.
Progestogen test Endometrium Total
Active Inactive
Positive 22 28 50
Negative 6 94 100
Total 28 122 150
Sensitivity = 78.57%
Specificity = 77.05%
Positive predictive value = 44%
Negative predictive value = 94%
regardless of the result. When the response to the test is
positive, atrophic states of the uterine mucosa are detected.
Thus, an anatomopathological study of the endometrium
of women with a positive test revealed atrophy in 36.9 to
50.6 percent.13.18.26-2H
Our results showed endometrial atrophy in 56 percent
of the women with a positive test, in agreement with
recorded values. This bleeding of the atrophic
endometrium during the postmenopausal period may be
due to sclerotic degeneration of the endometrial veins, or
to local or systemic hypertension, especially in women
with senile arteriosclerosis and endometritis.2fi Also, it 'is
possible that bleeding after the use of progestogen is due
to minute foci of active endometrium interspersed
throughout an almost completely atrophied mucosaY
However, a negative test usually reflects endometrial
inactivity. An active endometrium is detected in 3.4 to 10
percent of the women with a negative test. I1.15.27.29
In our series, we obtained a 6 percent rate of
false-negative results, i.e., six cases of active
endometrium in women with a negative progestogen
challenge test (Table 2). No hyperplasia was observed
among women with a negative progestogen challenge
test. Thus, we may conclude that the progestogen
challenge test is of paramount importance when its
result is negative, with a negative predictive value of
94 percent. However, when the response to the test is
positive, regressive states of the uterine mucosa are
detected, as emphasized by several investigators.IH.21.27.29
These data show that the sensitivity of the progestogen
challenge test in detecting endometrial alterations was 78.57
percent and its specificity (the ability to identify women
with an atrophic endometrium) was 77.05 percent. The
positive predictive value of the test was calculated at 44
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percent, indicating that, when the test is positive, endometrial
activity is present in 44 percent of cases.
On this basis, in the evaluation of the uterine mucosa
during the postmenopausal period, we believe that the
progestogen challenge test, when negative, is reassuring
to the physician. However, when the test is positive, other
methods, such as transvaginal ultrasonography should be
1171
associated with it. In this way, curettage can be avoided
from the start, because in more than 50 percent of cases in
which the test is positive, the endometrium is atrophic.
Therefore, we believe that the progestogen challenge test
and transvaginal ultrasonography, performed on
postmenopausal women, can determine those requiring
other exams, such as hysteroscopy or curettage.
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